Renal outcome after ciclosporin-induced nephrotoxicity

Nephrology Dialysis Transplantation

Volumn 22, Issue 3, 2007, Pages 880-885

  Tostivint, Isabelle ^a   du Montcel, Sophie Tezenas ^a   Jaudon, Marie Chantal ^a   Mallet, Alain ^a   Le Hoang, Phuc ^a   Bodaghi, Bahram ^a   Deray, Gilbert ^a   Bagnis, Corinne Isnard ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Ciclosporin; Glomerular filtration rate; Hypertension; Nephrotoxicity; Reversibility; Uveitis

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UVEITIS;

ADULT; AGED; BLOOD GLUCOSE; COLORIMETRY; CREATININE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; URIC ACID; UVEITIS;

EID: 33847624042     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl634     Document Type: Article

References (34)

1. Le Hoang P, Girard B, Deray G et al. Cyclosporine in the treatment of Birdshot retinochoroidopathy. Transplant Proc 1988; 20: 128-130
2. Deray G, Benhmida M, Le Hoang P et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992; 117: 578-583
3. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: Follow-up study. J Am Soc Nephrol 2002; 13: 2962-2968
4. Mihatsch MJ, Antonovych T, Bohman SO et al. Cyclosporin A nephropathy: standardization of the evaluation of kidney biopsies. Clin Nephrol 1994; 41: 23-32
5. Greenberg A, Thompson ME, Griffith BJ et al. Cyclosporine nephrotoxicity in cardiac allograft patients - a seven-year follow-up. Transplantation 1990; 50: 589-593
6. Dorent R, Tezenas S, Ghossoub JJ et al. Long-term use of cyclosporine in cardiac transplantation: The Pitie experience. Transplant Proc 2002; 34: 831-833
7. Senechal M, Dorent R, du Montcel ST et al. End-stage renal failure and cardiac mortality after heart transplantation. Clin Transplant 2004; 18: 1-6
8. Tedoriya T, Keogh AM, Kusano K et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 2002; 21: 976-982
9. Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001; 357: 587-591
10. Neau-Cransac M, Morel D, Bernard PH et al. Renal failure after liver transplantation: Outcome after calcineurin inhibitor withdrawal. Clin Transplant 2002; 16: 368-373
11. Thervet E, Morelon E, Ducloux D et al. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion. Clin Transplant 2000; 14: 561-566
12. Pascual M, Curtis J, Delmonico FL et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75: 1501-1505
13. Weir MR, Blahut S, Drachenburg C et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24: 379-386
14. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817
15. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365-1373
16. Kvien TK, Zeidler HK, Hannonen P et al. Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: A three year study of radiographic progression, renal function, and arterial hypertension. Ann Rheum Dis 2002; 61: 511-516
17. Garcia-Bustinduy M, Escoda M, Guimera FJ et al. Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: A retrospective case series. J Eur Acad Dermatol Venereol 2004; 18: 169-172
18. Assan R, Blanchet F, Feutren G et al. Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients. Diabetes Metab Res Rev 2002; 18: 464-472
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470
20. Li C, Yang CW, Kim WY et al. Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine. Am J Physiol Renal Physiol 2003; 284: F389-F398
21. Li C, Lim SW, Sun BK et al. Expression of apoptosis-related factors in chronic cyclosporine nephrotoxicity after cyclosporine withdrawal. Acta Pharmacol Sin 2004; 25: 401-411
22. Kang DH, Kim YG, Andoh TF et al. Post-cyclosporine-mediated hypertension and nephropathy: Amelioration by vascular endothelial growth factor. Am J Physiol Renal Physiol 2001; 280: F727-F736
23. Morozumi K, Thiel G, Albert FW, Banfi G, Gudat F, Mihatsch MJ. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Clin Nephrol 1992; 38: 1-8
24. Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004; 38: 73-77
25. Ishida K, Ishida H, Narita M et al. Factors affecting renal function in 119 985 adults over three years. Q J Med 2001; 94: 541-550
26. Kozel MM, Sabroe RA. Chronic urticaria: Aetiology, management and current and future treatment options. Drugs 2004; 64: 2515-2536
27. Matsuda M, Hoshi K, Gono T, Morita H, Ikeda S. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004; 224: 29-35
28. Corrigan CJ. Asthma refractory to glucocorticoids: The role of newer immunosuppressants. Am J Respir Med 2002; 1: 47-54
29. Alvarez F. Treatment of autoimmune hepatitis: Current and future therapies. Curr Treat Options Gastroenterol 2004; 7: 413-420
30. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002; 6: 537-562, ix
31. Gagliardi MG, Bevilacqua M, Bassano C et al. Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy. Heart 2004; 90: 1167-1171
32. Tomomasa T, Kobayashi A, Ushijima K et al. Guidelines for treatment of ulcerative colitis in children. Pediatr Int 2004; 46: 494-496
33. Goldenberg NA, Graham DK, Liang X, Hays T. Successful treatment of severe aplastic anemia in children using standardized immunosuppressive therapy with antithymocyte globulin and cyclosporine A. Pediatr Blood Cancer 2004; 43: 718-722
34. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305